Hefei Hengxin Life Science and Technology Co., Ltd. (SHE:301501)
China · Delayed Price · Currency is CNY 28.75
+0.01 (0.03%)
May 28, 2026, 3:04 PM CST
SHE:301501 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,838 | 1,807 | 1,562 | 1,396 | 1,054 | 696.15 |
Other Revenue | 38.01 | 38.01 | 32.38 | 29.51 | 33.89 | 22.75 |
| 1,876 | 1,845 | 1,594 | 1,425 | 1,088 | 718.9 | |
Revenue Growth (YoY) | 11.97% | 15.73% | 11.86% | 30.95% | 51.38% | 69.37% |
Cost of Revenue | 1,454 | 1,408 | 1,178 | 1,023 | 786.93 | 524.89 |
Gross Profit | 422.07 | 437.07 | 416.22 | 401.63 | 301.34 | 194.01 |
Selling, General & Admin | 134.88 | 132.6 | 100.29 | 93.46 | 70.71 | 51.85 |
Research & Development | 52.63 | 52.84 | 53.37 | 44.21 | 35.91 | 32.15 |
Other Operating Expenses | 9.11 | 9.69 | 6.93 | 6.04 | 4.29 | 4.23 |
Operating Expenses | 194.74 | 196.22 | 161.48 | 146.94 | 113.04 | 88.65 |
Operating Income | 227.34 | 240.85 | 254.74 | 254.69 | 188.3 | 105.36 |
Interest Expense | -6.05 | -7.45 | -10.03 | -5.31 | -4.41 | -2.62 |
Interest & Investment Income | 5.16 | 5.07 | 2.35 | 3.01 | 1.66 | 1.03 |
Currency Exchange Gain (Loss) | 1.69 | 1.69 | 5.91 | 3.65 | 7.03 | -2.4 |
Other Non Operating Income (Expenses) | -48.04 | -0.78 | -0.44 | -0.39 | -0.33 | -0.26 |
EBT Excluding Unusual Items | 180.1 | 239.38 | 252.53 | 255.65 | 192.25 | 101.11 |
Gain (Loss) on Sale of Investments | 5.77 | 4.64 | -0 | -2.14 | -5.5 | -11.29 |
Gain (Loss) on Sale of Assets | -0.26 | 0.34 | 0.88 | -0.3 | 0.24 | 0.05 |
Asset Writedown | -4.47 | -3.67 | -0.51 | -2.41 | -1.17 | -0.01 |
Other Unusual Items | 48.78 | 48.78 | 8.04 | 7.2 | 6.08 | 4.08 |
Pretax Income | 229.92 | 289.46 | 260.95 | 258.01 | 191.91 | 93.94 |
Income Tax Expense | 48.6 | 56.86 | 34.2 | 36.56 | 25.95 | 12.86 |
Earnings From Continuing Operations | 181.32 | 232.6 | 226.75 | 221.46 | 165.95 | 81.08 |
Minority Interest in Earnings | -7.05 | -8.76 | -6.86 | -7.59 | -3.19 | -0.92 |
Net Income | 174.27 | 223.84 | 219.89 | 213.86 | 162.77 | 80.16 |
Net Income to Common | 174.27 | 223.84 | 219.89 | 213.86 | 162.77 | 80.16 |
Net Income Growth | -31.98% | 1.80% | 2.82% | 31.39% | 103.04% | 207.30% |
Shares Outstanding (Basic) | 141 | 139 | 111 | 111 | 111 | 105 |
Shares Outstanding (Diluted) | 141 | 139 | 111 | 111 | 111 | 105 |
Shares Change (YoY) | 19.60% | 25.00% | 0.16% | -0.04% | 5.81% | - |
EPS (Basic) | 1.24 | 1.61 | 1.98 | 1.93 | 1.47 | 0.77 |
EPS (Diluted) | 1.24 | 1.61 | 1.98 | 1.93 | 1.47 | 0.77 |
EPS Growth | -43.13% | -18.56% | 2.66% | 31.45% | 91.90% | - |
Free Cash Flow | -181.84 | -188.4 | -78.75 | -110.86 | 2.58 | 9.75 |
Free Cash Flow Per Share | -1.29 | -1.36 | -0.71 | -1.00 | 0.02 | 0.09 |
Dividend Per Share | 0.350 | 0.350 | 0.345 | - | - | - |
Dividend Growth | 1.51% | 1.51% | - | - | - | - |
Gross Margin | 22.50% | 23.69% | 26.11% | 28.18% | 27.69% | 26.99% |
Operating Margin | 12.12% | 13.05% | 15.98% | 17.87% | 17.30% | 14.66% |
Profit Margin | 9.29% | 12.13% | 13.79% | 15.01% | 14.96% | 11.15% |
Free Cash Flow Margin | -9.69% | -10.21% | -4.94% | -7.78% | 0.24% | 1.36% |
EBITDA | 334.29 | 339.93 | 322.36 | 297.44 | 221.74 | 129.15 |
EBITDA Margin | 17.82% | 18.43% | 20.22% | 20.87% | 20.38% | 17.96% |
D&A For EBITDA | 106.95 | 99.08 | 67.62 | 42.75 | 33.43 | 23.79 |
EBIT | 227.34 | 240.85 | 254.74 | 254.69 | 188.3 | 105.36 |
EBIT Margin | 12.12% | 13.05% | 15.98% | 17.87% | 17.30% | 14.66% |
Effective Tax Rate | 21.14% | 19.65% | 13.11% | 14.17% | 13.52% | 13.69% |
Revenue as Reported | 1,876 | 1,845 | 1,594 | 1,425 | 1,088 | 718.9 |
Advertising Expenses | - | 2.34 | 2.55 | 2 | 0.55 | 1.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.